Effect of dalfampridine on information processing speed impairment in multiple sclerosis

Area of Science:

• Neurology
• Neuroscience
• Clinical Trials

Background:

• Cognitive impairment, particularly in information processing speed (IPS), is a significant challenge for individuals with multiple sclerosis (MS).
• Assessing and treating IPS deficits is crucial for improving daily functioning in MS patients.

Purpose of the Study:

• To evaluate the efficacy of dalfampridine in enhancing information processing speed (IPS) in patients with multiple sclerosis (MS) experiencing cognitive impairment.
• To determine if dalfampridine can offer a therapeutic benefit for cognitive deficits in MS.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 120 MS patients with below-average Symbol Digit Modalities Test (SDMT) scores.
• Participants received either 10 mg of dalfampridine or a placebo twice daily for 12 weeks, with comprehensive neuropsychological testing at baseline, end of treatment, and follow-up.
• The primary endpoint was the improvement in SDMT scores.

Main Results:

• The dalfampridine group showed a statistically significant increase in SDMT scores compared to the placebo group (p = 0.0018 for raw scores, p = 0.0013 for z-scores).
• Improvements in IPS were observed in the dalfampridine group, with a mean change of 9.9 in raw SDMT scores versus 5.2 in the placebo group.
• While the primary endpoint was met, the benefits were not sustained at the 4-week follow-up; however, positive effects were noted on the Paced Auditory Serial Addition Test and cognitive fatigue.

Conclusions:

• Dalfampridine demonstrates potential as an effective treatment for improving information processing speed in patients with multiple sclerosis.
• The study provides Class I evidence supporting the use of dalfampridine for IPS deficits in MS patients with low SDMT scores.